Details of the Drug
General Information of Drug (ID: DM75CXN)
Drug Name |
Avanafil
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms | Stendra (TN) | ||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 483.9 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 9 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 9 | ||||||||||||||||||||||
ADMET Property |
|
||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | ||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug-Metabolizing Enzyme (DME) |
|
||||||||||||||||||||||||||
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Erectile dysfunction | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | HA01.1 | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Disease Different from Avanafil (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7448). | ||||
---|---|---|---|---|---|
2 | FDA Approved Drug Products: Stendra (avanafil) tablets for oral use | ||||
3 | EMA CHMP Assessment Report: Avanafil (INN) | ||||
4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
5 | An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013 Jul;14(10):1333-44. | ||||
6 | Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA. | ||||
7 | Cerner Multum, Inc. "Australian Product Information.". | ||||
8 | Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA. | ||||
9 | Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ. | ||||
10 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
11 | Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424] | ||||
12 | Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN. | ||||
13 | EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.". | ||||
14 | Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ. | ||||
15 | Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA. | ||||
16 | Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA. | ||||
17 | Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143] | ||||
18 | Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA. | ||||